| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5325 | 2021 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1335 | 2021 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 739 | 2021 |
| Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised … X Liu, RH Shaw, ASV Stuart, M Greenland, PK Aley, NJ Andrews, ... The Lancet 398 (10303), 856-869, 2021 | 492 | 2021 |
| Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data RH Shaw, A Stuart, M Greenland, X Liu, JSN Van-Tam, MD Snape The Lancet 397 (10289), 2043-2046, 2021 | 325 | 2021 |
| Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a … ASV Stuart, RH Shaw, X Liu, M Greenland, PK Aley, NJ Andrews, ... The Lancet 399 (10319), 36-49, 2022 | 215 | 2022 |
| Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial LC Chappell, P Brocklehurst, ME Green, R Hunter, P Hardy, E Juszczak, ... The Lancet 394 (10204), 1181-1190, 2019 | 166 | 2019 |
| Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial F Qadri, F Khanam, X Liu, K Theiss-Nyland, PK Biswas, AI Bhuiyan, ... The Lancet 398 (10301), 675-684, 2021 | 91 | 2021 |
| Contemporary incidence and prevalence of rheumatic fever and rheumatic heart disease in Australia using linked data: the case for policy change JM Katzenellenbogen, D Bond‐Smith, RJ Seth, K Dempsey, J Cannon, ... Journal of the American Heart Association 9 (19), e016851, 2020 | 90 | 2020 |
| Safety and immunogenicity report from the com-COV study–a single-blind randomised non-inferiority trial comparing heterologous and homologous prime-boost schedules with an … X Liu, RH Shaw, ASV Stuart, M Greenland, T Dinesh, ... | 58 | 2021 |
| COVID-19 Genomics UK consortium; AMPHEUS Project KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... Oxford COVID-19 Vaccine Trial Group. Efficacy of ChAdOx1 nCoV-19 (AZD1222 …, 2021 | 52 | 2021 |
| The microbiome of infants recruited to a randomised placebo-controlled probiotic trial (PiPS trial) M Millar, J Seale, M Greenland, P Hardy, E Juszczak, M Wilks, N Panton, ... EBioMedicine 20, 255-262, 2017 | 40 | 2017 |
| Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com … RH Shaw, X Liu, ASV Stuart, M Greenland, PK Aley, NJ Andrews, ... The Lancet Respiratory Medicine 10 (11), 1049-1060, 2022 | 39 | 2022 |
| Missing voices: profile, extent, and 12-month outcomes of nonfatal traumatic brain injury in Aboriginal and non-Aboriginal adults in Western Australia using linked … JM Katzenellenbogen, E Atkins, SC Thompson, D Hersh, J Coffin, ... The Journal of head trauma rehabilitation 33 (6), 412-423, 2018 | 36 | 2018 |
| Greater adherence to secondary prevention medications improves survival after stroke or transient ischemic attack: a linked registry study LL Dalli, J Kim, DA Cadilhac, M Greenland, FM Sanfilippo, NE Andrew, ... Stroke, 2021 | 33 | 2021 |
| Operationalization and validation of a novel method to calculate adherence to polypharmacy with refill data from the Australian pharmaceutical benefits scheme (PBS) database I Arnet, M Greenland, MW Knuiman, JM Rankin, J Hung, L Nedkoff, ... Clinical epidemiology, 1181-1194, 2018 | 25 | 2018 |
| Comparative trends in coronary heart disease subgroup hospitalisation rates in England and Australia L Nedkoff, R Goldacre, M Greenland, MJ Goldacre, D Lopez, N Hall, ... Heart 105 (17), 1343-1350, 2019 | 19 | 2019 |
| Phase 1/2a safety and immunogenicity of an adenovirus 26 vector respiratory syncytial virus (RSV) vaccine encoding prefusion F in adults 18–50 years and RSV-seropositive … ASV Stuart, M Virta, K Williams, I Seppa, R Hartvickson, M Greenland, ... The Journal of infectious diseases 227 (1), 71-82, 2023 | 17 | 2023 |
| Cardioprotective medication adherence in Western Australians in the first year after myocardial infarction: restricted cubic spline analysis of adherence-outcome relationships M Greenland, MW Knuiman, J Hung, L Nedkoff, I Arnet, JM Rankin, ... Scientific reports 10 (1), 4315, 2020 | 14 | 2020 |
| Towards better reporting of the proportion of days covered method in cardiovascular medication adherence: A scoping review and new tool TEN‐SPIDERS LL Dalli, MF Kilkenny, I Arnet, FM Sanfilippo, DM Cummings, MK Kapral, ... British Journal of Clinical Pharmacology 88 (10), 4427-4442, 2022 | 12 | 2022 |
